Opendata, web and dolomites

ProMeta SIGNED

Non-histone protein acetylation targets of KAT2A in AML

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ProMeta project word cloud

Explore the words cloud of the ProMeta project. It provides you a very rough idea of what is the project "ProMeta" about.

heterogeneous    identity    ing    aml    residues    prognosis    mutation    acetylation    30    developmental    survival    acetylates    regulates    gcn5    modifications    evi1    transferase    function    deranged    driving    decades    cell    mds1    peroxisome    coactivator    interests    alpha    yeast    hat    pkc412    rare    food       mutated    paves    found    protein    disease    expansion    stages    translational    care    myeloid    proteins    blasts    implicated    acetyl    epigenetic    chains    modifiers    attributable    complexes    reprogramming    accompanying    post    supportive    small    maintained    break    essentially    dysregulation    bone    investigation    diseases    activated    fda    clonal    proliferator    first    transcriptional    crucially    oncogenic    biology    explore    transplantation    cancer    designation    itd    administration    mainstay    maturation    fate    hijacked    patients    aml1    extends    signalling    drug    receptor    considering    fusion    themes    acetyltransferase    pivotal    unchanged    therapy    catalyse    marrow    acute    leukaemia    gamma    kat2a    histone    flt3    remained    dismal    received    free    pathogenesis   

Project "ProMeta" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 183˙454.00

Map

 Project objective

The importance of an insight into how cell fate is established and maintained, extends far beyond the interests of developmental biology. It is pivotal to our understanding of how these processes can be hijacked and deranged in diseases such as cancer, or of the factors involved in reprogramming cell identity and function. Acute Myeloid Leukaemia (AML) has a dismal prognosis with less than 30% 5-year survival. Mainstay therapy has remained essentially unchanged for the past three decades, with all small advances in disease-free survival attributable to transplantation and improved supportive care. Only recently PKC412 has received Food and Drug Administration (FDA)’s break through therapy designation for the FLT3-ITD AML. This paves the way for investigation considering that FLT3-ITD as a driving oncogenic mutation has been found in ~30% of the AML patients. The pathogenesis of AML is heterogeneous, but there are common themes of epigenetic, transcriptional and signalling dysregulation that contribute to the resulting clonal expansion of blasts at different stages of maturation, and accompanying bone marrow failure. A significant number of the most commonly mutated targets in AML are histone modifiers, i.e. proteins or complexes that catalyse post-translational modifications in specific residues of the histone side chains. A less studied acetyltransferase, but crucially implicated in AML is KAT2A, the first histone acetyl-transferase (HAT) identified in yeast.GCN5 also acetylates the AML1/MDS1/EVI1 fusion protein in rare cases of AML.KAT2A regulates the activity of Peroxisome Proliferator- Activated Receptor Gamma-Coactivator-1α and B through protein acetylation. The goal of this proposal is to explore the role of KAT2A in Acute Myeloid Leukaemia (AML) through investigation of its non-histone protein acetylation activity.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROMETA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROMETA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

IRF4 Degradation (2019)

Using a novel protein degradation approach to uncover IRF4-regulated genes in plasma cells

Read More  

SCAPA (2019)

Functional analysis of Alternative Polyadenylation during neuronal differentiation at single cell resolution

Read More